A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer

Summary

This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective response rate (ORR). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.

Timeline

Start

2024-09-11

Primary completion

2028-05-01

Completion

2028-11-01

Drugs

Indications